Biomm S.A Cash Flow Conversion Efficiency

Latest as of September 2025: -0.164x

Biomm S.A cash flow conversion efficiency. Based on the latest financial reports, Biomm S.A (BIOM3) has a cash flow conversion efficiency ratio of -0.164x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$-46.72 Million ≈ $-9.17 Million USD) by net assets (R$284.10 Million ≈ $55.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Biomm S.A (2006–2024)

Cash flow conversion efficiency of Biomm S.A from 2006 to 2024. This chart illustrates how Biomm S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Biomm S.A (BIOM3) share price today for real-time trading data and today's change.

Biomm S.A Cash Flow Conversion Ratio Explained

Biomm S.A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Biomm S.A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Biomm S.A ranked by their cash flow conversion efficiency. Also see Biomm S.A (BIOM3) total market value for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Bioversys AG
SW:BIOV
N/A
Karsan Otomotiv Sanayi ve Ticaret AS
IS:KARSN
0.313x
Nordic Halibut AS
OL:NOHAL
0.009x
Gia Lai Electricity JSC
VN:GEG
0.076x
SANIONA AB (PUBL)
F:30S
-0.121x
LaFayette Acquisition Corp. Ordinary Share
NASDAQ:LAFA
-0.002x
LongDa Construction & Development Corp
TW:5519
-0.025x
Cti Logistics Ltd
AU:CLX
0.142x

Annual Cash Flow Conversion Efficiency for Biomm S.A (2006–2024)

The table below shows the annual cash flow conversion efficiency of Biomm S.A from 2006 to 2024. Review Biomm S.A free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 R$262.78 Million
≈ $51.56 Million
R$-91.84 Million
≈ $-18.02 Million
-0.350x +42.54%
2023-12-31 R$122.94 Million
≈ $24.12 Million
R$-74.78 Million
≈ $-14.67 Million
-0.608x -53.63%
2022-12-31 R$159.11 Million
≈ $31.22 Million
R$-63.00 Million
≈ $-12.36 Million
-0.396x +52.89%
2021-12-31 R$111.59 Million
≈ $21.90 Million
R$-93.78 Million
≈ $-18.40 Million
-0.840x -66.12%
2020-12-31 R$191.48 Million
≈ $37.57 Million
R$-96.87 Million
≈ $-19.01 Million
-0.506x -0.11%
2019-12-31 R$153.56 Million
≈ $30.13 Million
R$-77.61 Million
≈ $-15.23 Million
-0.505x -21.54%
2018-12-31 R$106.09 Million
≈ $20.82 Million
R$-44.12 Million
≈ $-8.66 Million
-0.416x +54.67%
2017-12-31 R$59.30 Million
≈ $11.64 Million
R$-54.41 Million
≈ $-10.68 Million
-0.917x -58.00%
2016-12-31 R$65.93 Million
≈ $12.94 Million
R$-38.28 Million
≈ $-7.51 Million
-0.581x -380.95%
2015-12-31 R$115.13 Million
≈ $22.59 Million
R$-13.90 Million
≈ $-2.73 Million
-0.121x +34.64%
2014-12-31 R$107.10 Million
≈ $21.02 Million
R$-19.78 Million
≈ $-3.88 Million
-0.185x -91.50%
2013-12-31 R$108.94 Million
≈ $21.38 Million
R$-10.51 Million
≈ $-2.06 Million
-0.096x -129.36%
2012-12-31 R$-22.00 Million
≈ $-4.32 Million
R$-7.23 Million
≈ $-1.42 Million
0.329x +61.48%
2011-12-31 R$-8.76 Million
≈ $-1.72 Million
R$-1.78 Million
≈ $-349.66K
0.203x -82.19%
2010-12-31 R$-4.06 Million
≈ $-796.84K
R$-4.64 Million
≈ $-910.45K
1.143x -99.77%
2009-12-31 R$-15.00K
≈ $-2.94K
R$-7.50 Million
≈ $-1.47 Million
499.733x +106719.64%
2008-12-31 R$-12.22 Million
≈ $-2.40 Million
R$-5.71 Million
≈ $-1.12 Million
0.468x -30.15%
2006-12-31 R$3.09 Million
≈ $606.12K
R$2.07 Million
≈ $405.98K
0.670x --

About Biomm S.A

SA:BIOM3 Brazil Biotechnology
Market Cap
$159.23 Million
R$811.47 Million BRL
Market Cap Rank
#17182 Global
#165 in Brazil
Share Price
R$5.93
Change (1 day)
+7.82%
52-Week Range
R$5.05 - R$9.50
All Time High
R$23.65
About

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more